IRIS
BUCCISANO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 45.123
EU - Europa 4.872
AS - Asia 2.906
SA - Sud America 224
AF - Africa 42
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 13
Totale 53.215
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 45.060
DE - Germania 1.250
SG - Singapore 1.224
IT - Italia 1.014
CN - Cina 765
UA - Ucraina 615
IE - Irlanda 538
RU - Federazione Russa 407
HK - Hong Kong 347
GB - Regno Unito 291
KR - Corea 232
FR - Francia 184
BR - Brasile 171
FI - Finlandia 153
SE - Svezia 143
IN - India 71
NL - Olanda 70
PL - Polonia 48
AT - Austria 41
CA - Canada 41
ID - Indonesia 40
AU - Australia 31
BE - Belgio 29
EG - Egitto 27
JP - Giappone 27
IR - Iran 26
PH - Filippine 20
UZ - Uzbekistan 20
VN - Vietnam 20
ES - Italia 18
MX - Messico 17
TR - Turchia 17
PE - Perù 16
PK - Pakistan 16
IQ - Iraq 14
TH - Thailandia 13
CL - Cile 12
CH - Svizzera 10
CZ - Repubblica Ceca 10
AR - Argentina 9
EU - Europa 9
TW - Taiwan 9
MY - Malesia 8
RO - Romania 8
SA - Arabia Saudita 8
PT - Portogallo 7
BD - Bangladesh 5
CO - Colombia 5
GR - Grecia 5
IL - Israele 5
RS - Serbia 5
VE - Venezuela 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CR - Costa Rica 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
AE - Emirati Arabi Uniti 3
EC - Ecuador 3
KG - Kirghizistan 3
LT - Lituania 3
NZ - Nuova Zelanda 3
ZA - Sudafrica 3
BH - Bahrain 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
KE - Kenya 2
MA - Marocco 2
NG - Nigeria 2
QA - Qatar 2
SD - Sudan 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
DK - Danimarca 1
DZ - Algeria 1
FJ - Figi 1
GE - Georgia 1
GT - Guatemala 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
PS - Palestinian Territory 1
PY - Paraguay 1
SN - Senegal 1
TN - Tunisia 1
Totale 53.215
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.566
Wilmington 11.985
Houston 9.181
Fairfield 1.533
Ann Arbor 1.086
Chandler 1.080
Singapore 878
Ashburn 867
Seattle 656
Jacksonville 535
Cambridge 531
Dublin 482
Dearborn 384
Rome 360
Medford 352
New York 341
Hong Kong 328
Beijing 256
Santa Clara 223
Lawrence 164
Zhengzhou 152
Boardman 100
San Diego 82
Milan 79
Moscow 74
Menlo Park 60
Mülheim 59
Council Bluffs 55
Creede 51
Shanghai 48
Redwood City 46
Engelhard 44
London 41
Nanjing 40
Hefei 34
Jakarta 32
Bologna 29
Norwalk 29
Nuremberg 29
Guangzhou 28
Los Angeles 28
Kraków 27
Munich 27
Brussels 26
Kunming 26
Center 25
Seoul 25
Helsinki 24
University Park 24
Falls Church 22
Hangzhou 21
Palo Alto 21
The Dalles 21
Toronto 20
Verona 19
Florence 16
Mountain View 16
Nürnberg 15
Paris 15
Pune 15
Dong Ket 14
Lima 14
Frankfurt am Main 13
Chicago 12
Nanchang 12
Naples 12
Vienna 12
Bang Bai Mai 11
Chiswick 11
Lappeenranta 11
North Bergen 11
Saint Petersburg 11
São Paulo 11
Turin 11
Ahmedabad 10
Brno 10
Hackensack 10
Fuzhou 9
Jinan 9
Kilburn 9
Manila 9
Washington 9
Cairo 8
Detroit 8
Groningen 8
Hounslow 8
Mumbai 8
San Francisco 8
San Jose 8
Warsaw 8
Wuhan 8
Baghdad 7
Birmingham 7
Hebei 7
Innsbruck 7
Phoenix 7
Redmond 7
Rio de Janeiro 7
Roebling 7
Torre Del Greco 7
Totale 46.709
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 612
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 561
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 483
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 481
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 473
An unusual endoscopic finding in a patient with melena: Multiple gastric ulcers of regular shape 463
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 460
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 457
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 455
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 451
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 450
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 449
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 443
Clinical significance of CD38 expression in chronic lymphocytic leukemia 442
CD7 expression in acute myeloid leukemia 442
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 440
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 439
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 436
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 434
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 432
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 431
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 430
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 429
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 427
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 427
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 427
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 425
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 425
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 422
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 421
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 421
Cord blood transplantation in adults with acute myeloid leukaemia. 418
Biological features of acute myeloid leukemia in the elderly 418
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 417
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 415
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 410
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 410
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 409
AML-M0: a biological and clinical profile 406
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 402
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 400
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 398
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 395
Blood stem cell processing 390
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 390
Azacitidine for the treatment of patients with acute myeloid leukemia 389
Biological pattern of AML-M0 versus AML-M1: Response 389
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 387
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 387
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 387
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 387
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 385
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 385
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 384
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 384
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 383
P-glycoprotein expression in de novo acute myeloid leukemia 383
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 383
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study 381
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 381
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 381
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 380
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 378
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 373
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 372
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 371
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 369
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 369
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 367
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 367
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 366
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors 363
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 362
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 362
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 362
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 362
Monitoring of minimal residual disease in acute myeloid leukemia 361
Outcomes of allogeneic stem cell transplantation for secondary therapy-related acute myeloid leukaemia 360
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 359
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. 358
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 358
Treatment of low-blast count AML using hypomethylating agents 358
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 357
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 355
Reversible hyporegenerative anemia during natalizumab treatment 355
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 353
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 352
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 350
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 348
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 347
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 346
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 345
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 344
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 341
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 341
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 339
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 335
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 335
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 333
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 332
Totale 39.707
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.416
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.734 0 0 0 0 0 0 0 0 1.055 1.076 733 870
2020/20217.478 840 865 745 1.008 769 713 951 711 229 219 328 100
2021/20221.970 66 193 81 67 54 194 131 129 167 177 136 575
2022/20232.915 285 232 218 295 198 569 331 188 331 51 161 56
2023/20241.656 137 48 197 49 136 502 78 112 40 47 43 267
2024/20253.438 172 978 519 278 111 321 318 252 489 0 0 0
Totale 53.939